NCT04024696View on ClinicalTrials.gov

A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 8, 2020

Primary Completion Date

December 30, 2024

Study Completion Date

November 30, 2025

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

Abexinostat

Abexinostat Tosylate Tablets

Trial Locations (4)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

221006

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

300052

Tianjin Medical University General Hospital, Tianjin

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Xynomic Pharmaceuticals, Inc.

INDUSTRY

NCT04024696 - A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients | Biotech Hunter | Biotech Hunter